Alpha Cognition Inc (ACOG)

$6.53 +0.16 (2.51%)
Market Cap 141.98M
Revenue (ttm) 0.00
Net Income (ttm) -14.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 85,500
Avg Vol 104,824
Day's Range N/A - N/A
Shares Out 21.74M
Stochastic %K 90%
Beta 2.62
Analysts Sell
Price Target $18.00

Company Profile

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatit...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 564 9244
Address:
750 West Pender Street, Suite 1200, Vancouver, Canada
Bioinvester001
Bioinvester001 Dec. 5 at 5:07 PM
$ACOG FDA just announced more lax requirements regarding the number of studies required for NDA acceptance/approval of medical drugs. Bomb blast study for NDA could be fast forwarded here.
0 · Reply
Bioinvester001
Bioinvester001 Dec. 4 at 3:43 PM
$ACOG Legacy investors are continuing to sell, and are trading shares with buying institutional investors. This process is holding the sp down, and makes this a great long term investment in my opinion. Adding as usual on a steady basis. Highlight of Titan Partners chat is the company is gathering data regarding behavioral conditions and there is a focus on how the drug mitigates these negative conditions. Also, CMS royalty payment by q1. Sales also appear to accelerative with repeated orders in addition to new accounts. See Mobile Dish over on Redditt.
0 · Reply
Psuedo_Doji
Psuedo_Doji Dec. 3 at 9:45 PM
$ACOG nice to see some volume today
0 · Reply
ForestFoxes
ForestFoxes Dec. 3 at 5:49 AM
$ACOG transcripts on Seeking Alpha for those who have an account: https://seekingalpha.com/article/4849436-alpha-cognition-inc-acog-discusses-commercial-adoption-metrics-and-market-opportunity-in-long I listened to it live, and there was one other listener here on Stocktwits. For a few moments, there was one extra person. The stock is clearly not followed. The talk was very good. Many, many questions were asked and all of them were answered thoroughly with the exception of the ones where it was mentioned they would not break down those figures.
2 · Reply
FlowerInTheCellar
FlowerInTheCellar Dec. 2 at 9:31 PM
$ACOG https://www.businesswire.com/news/home/20251201982685/en/Alpha-Cognition-to-Participate-in-Virtual-Fireside-Chat-Hosted-by-Titan-Partners Some Late 🙈
0 · Reply
OldManLogan
OldManLogan Dec. 2 at 6:36 PM
$ACOG Is there a replay of the call? Couldn't listen live.
0 · Reply
Psuedo_Doji
Psuedo_Doji Dec. 2 at 6:13 PM
$ACOG highlights of the chat? Was unable to join.
0 · Reply
ForestFoxes
ForestFoxes Nov. 22 at 7:42 AM
$ANVS CEO, Dr. Maccecchini, tells their patients and family to buy their stock because it's the ONLY way out ☹️ Negative-Sum for Society - Erosion of Trust: Scams undermine public confidence in the legitimate biotech sector, making it harder for genuine, high-risk, but potentially life-saving ventures to attract necessary funding. - Resource Misallocation: The capital funneled into fraudulent ventures is wasted instead of being invested in legitimate, value-creating biotech research that could lead to real medical advancements such as $ACOG which is already helping patients with an FDA approved drug on the market right now and companies likes $CGTX $GANX and $COYA
3 · Reply
Bioinvester001
Bioinvester001 Nov. 21 at 7:00 PM
$ACOG Payer accounts could double by year end, and there are several dedicated employees working exclusively with the insurance payers.
0 · Reply
Psuedo_Doji
Psuedo_Doji Nov. 21 at 5:41 PM
$ACOG have a great weekend, ACOG peeps. Undeniably
0 · Reply
Latest News on ACOG
Alpha Cognition Inc. (ACOG) Discusses Commercial Adoption Metrics and Market Opportunity in Long-Term Care Transcript

Dec 2, 2025, 6:53 PM EST - 5 days ago

Alpha Cognition Inc. (ACOG) Discusses Commercial Adoption Metrics and Market Opportunity in Long-Term Care Transcript

Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners

Dec 1, 2025, 5:51 PM EST - 6 days ago

Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025

Nov 14, 2025, 9:46 AM EST - 23 days ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025

Alpha Cognition Inc. (ACOG) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:11 PM EST - 24 days ago

Alpha Cognition Inc. (ACOG) Q3 2025 Earnings Call Transcript

Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 13, 2025, 4:00 PM EST - 24 days ago

Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update

Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025

Oct 30, 2025, 8:30 AM EDT - 5 weeks ago

Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025

Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings

Oct 14, 2025, 4:30 PM EDT - 7 weeks ago

Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings

Alpha Cognition to Present Clinical Data at ASCP Annual Meeting

Oct 6, 2025, 8:30 AM EDT - 2 months ago

Alpha Cognition to Present Clinical Data at ASCP Annual Meeting

Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares

Sep 30, 2025, 11:14 PM EDT - 2 months ago

Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares

Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares

Sep 30, 2025, 4:58 PM EDT - 2 months ago

Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares

Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences

Aug 28, 2025, 1:00 PM EDT - 3 months ago

Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025

Aug 15, 2025, 5:10 PM EDT - 4 months ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025

Alpha Cognition Inc. (ACOG) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:54 PM EDT - 4 months ago

Alpha Cognition Inc. (ACOG) Q2 2025 Earnings Call Transcript

Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 14, 2025, 8:30 AM EDT - 4 months ago

Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update

Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview

Aug 4, 2025, 8:30 AM EDT - 4 months ago

Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview

Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer's Disease

Jul 29, 2025, 8:30 AM EDT - 4 months ago

Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer's Disease

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer's Association International Conference

Jul 8, 2025, 8:30 AM EDT - 5 months ago

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer's Association International Conference

Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Jul 1, 2025, 5:05 PM EDT - 5 months ago

Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Alpha Cognition: Launching A Differentiated Drug Into A Large Alzheimer's Market Opportunity

May 19, 2025, 4:35 PM EDT - 7 months ago

Alpha Cognition: Launching A Differentiated Drug Into A Large Alzheimer's Market Opportunity

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025

May 19, 2025, 10:25 AM EDT - 7 months ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025

Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript

May 15, 2025, 9:51 PM EDT - 7 months ago

Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

May 15, 2025, 8:30 AM EDT - 7 months ago

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

May 1, 2025, 8:30 AM EDT - 7 months ago

Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 30, 2025, 7:30 AM EDT - 7 months ago

Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference

Apr 28, 2025, 8:30 AM EDT - 7 months ago

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

Apr 10, 2025, 8:30 AM EDT - 8 months ago

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Apr 1, 2025, 4:27 PM EDT - 8 months ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 9:50 PM EDT - 8 months ago

Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript

Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Mar 31, 2025, 8:30 AM EDT - 8 months ago

Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Mar 19, 2025, 4:30 PM EDT - 9 months ago

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease

Mar 18, 2025, 8:30 AM EDT - 9 months ago

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease

Feb 12, 2025, 8:30 AM EST - 10 months ago

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

Jan 30, 2025, 11:05 AM EST - 11 months ago

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Jan 14, 2025, 8:30 AM EST - 11 months ago

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in China

Jan 8, 2025, 8:30 AM EST - 11 months ago

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in China

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer's Long-Term Care Market During Investor Update Call

Jan 6, 2025, 8:30 AM EST - 11 months ago

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer's Long-Term Care Market During Investor Update Call

Alpha Cognition Announces Partial Exercise of Over-allotment Option

Dec 16, 2024, 2:56 PM EST - 1 year ago

Alpha Cognition Announces Partial Exercise of Over-allotment Option

CSE Bulletin: Delist - Alpha Cognition Inc. (ACOG)

Dec 16, 2024, 11:51 AM EST - 1 year ago

CSE Bulletin: Delist - Alpha Cognition Inc. (ACOG)

Alpha Cognition Announces Voluntary Delisting from CSE

Dec 12, 2024, 6:41 PM EST - 1 year ago

Alpha Cognition Announces Voluntary Delisting from CSE

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Dec 11, 2024, 8:30 AM EST - 1 year ago

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Nov 15, 2024, 5:00 PM EST - 1 year ago

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing

Nov 12, 2024, 9:22 AM EST - 1 year ago

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing

Bioinvester001
Bioinvester001 Dec. 5 at 5:07 PM
$ACOG FDA just announced more lax requirements regarding the number of studies required for NDA acceptance/approval of medical drugs. Bomb blast study for NDA could be fast forwarded here.
0 · Reply
Bioinvester001
Bioinvester001 Dec. 4 at 3:43 PM
$ACOG Legacy investors are continuing to sell, and are trading shares with buying institutional investors. This process is holding the sp down, and makes this a great long term investment in my opinion. Adding as usual on a steady basis. Highlight of Titan Partners chat is the company is gathering data regarding behavioral conditions and there is a focus on how the drug mitigates these negative conditions. Also, CMS royalty payment by q1. Sales also appear to accelerative with repeated orders in addition to new accounts. See Mobile Dish over on Redditt.
0 · Reply
Psuedo_Doji
Psuedo_Doji Dec. 3 at 9:45 PM
$ACOG nice to see some volume today
0 · Reply
ForestFoxes
ForestFoxes Dec. 3 at 5:49 AM
$ACOG transcripts on Seeking Alpha for those who have an account: https://seekingalpha.com/article/4849436-alpha-cognition-inc-acog-discusses-commercial-adoption-metrics-and-market-opportunity-in-long I listened to it live, and there was one other listener here on Stocktwits. For a few moments, there was one extra person. The stock is clearly not followed. The talk was very good. Many, many questions were asked and all of them were answered thoroughly with the exception of the ones where it was mentioned they would not break down those figures.
2 · Reply
FlowerInTheCellar
FlowerInTheCellar Dec. 2 at 9:31 PM
$ACOG https://www.businesswire.com/news/home/20251201982685/en/Alpha-Cognition-to-Participate-in-Virtual-Fireside-Chat-Hosted-by-Titan-Partners Some Late 🙈
0 · Reply
OldManLogan
OldManLogan Dec. 2 at 6:36 PM
$ACOG Is there a replay of the call? Couldn't listen live.
0 · Reply
Psuedo_Doji
Psuedo_Doji Dec. 2 at 6:13 PM
$ACOG highlights of the chat? Was unable to join.
0 · Reply
ForestFoxes
ForestFoxes Nov. 22 at 7:42 AM
$ANVS CEO, Dr. Maccecchini, tells their patients and family to buy their stock because it's the ONLY way out ☹️ Negative-Sum for Society - Erosion of Trust: Scams undermine public confidence in the legitimate biotech sector, making it harder for genuine, high-risk, but potentially life-saving ventures to attract necessary funding. - Resource Misallocation: The capital funneled into fraudulent ventures is wasted instead of being invested in legitimate, value-creating biotech research that could lead to real medical advancements such as $ACOG which is already helping patients with an FDA approved drug on the market right now and companies likes $CGTX $GANX and $COYA
3 · Reply
Bioinvester001
Bioinvester001 Nov. 21 at 7:00 PM
$ACOG Payer accounts could double by year end, and there are several dedicated employees working exclusively with the insurance payers.
0 · Reply
Psuedo_Doji
Psuedo_Doji Nov. 21 at 5:41 PM
$ACOG have a great weekend, ACOG peeps. Undeniably
0 · Reply
Toni19
Toni19 Nov. 16 at 11:26 AM
$ACOG https://biotechhealthx.com/biotech-news/why-alpha-cognition-acog-could-be-the-next-big-alzheimers-breakthrough-stock/
0 · Reply
BottomQuark
BottomQuark Nov. 15 at 12:40 PM
$ACOG Lauren speaking at a TSP Fierce Pharma webinar on 12/4: https://www.linkedin.com/posts/alpha-cognition-inc_biotech-leadership-is-changingand-the-strongest-activity-7395161427432521728-dUGY
0 · Reply
StockScanners
StockScanners Nov. 15 at 4:44 AM
$ACOG keep watch if this holds above 6.44
0 · Reply
Bioinvester001
Bioinvester001 Nov. 14 at 3:34 PM
$ACOG Legacy investors have been selling after earnings.
0 · Reply
newsfile_corp
newsfile_corp Nov. 14 at 2:47 PM
https://nfne.ws/274515 $ACOG @reportablenews #QuarterlyResults #NASDAQ #Investing
0 · Reply
Bioinvester001
Bioinvester001 Nov. 13 at 10:08 PM
$ACOG It appears accelerated sales is in the mix. Great long-term term investment.
0 · Reply
d_risk
d_risk Nov. 13 at 10:02 PM
$ACOG - Alpha Cognition Inc. - 10Q - Updated Risk Factors ACOG flags new risks from sweeping US tariffs and unresolved China trade tensions, plus ongoing material weakness in internal controls tied to warrant liability valuation, raising concerns over financial reporting accuracy and exposure to global economic uncertainty. #TradeTensions #GlobalEconomicUncertainty #FinancialReporting #InternalControls #Tariffs 🟢 Added 🟠 Removed https://d-risk.ai/ACOG/10-Q/2025-11-13
0 · Reply
FlowerInTheCellar
FlowerInTheCellar Nov. 13 at 9:11 PM
$ACOG https://www.businesswire.com/news/home/20251113670833/en/Alpha-Cognition-Inc.-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Operational-Update
1 · Reply
ForestFoxes
ForestFoxes Nov. 13 at 7:12 PM
I'm not a Substack user, but there's a chat about $ACOG if anyone is interested on that platform.
0 · Reply
StockScanners
StockScanners Nov. 13 at 3:25 AM
$ACOG reached 6.36
0 · Reply
Psuedo_Doji
Psuedo_Doji Nov. 12 at 5:28 PM
$ACOG thoughts on what we will see/hear from team during Q3 financials and business update tomorrow afternoon?
1 · Reply
BioTechHealthX
BioTechHealthX Nov. 9 at 7:41 AM
$ACOG Alpha Cognition is positioning itself as a leader in neurodegenerative treatment innovation with ZUNVEYL®. Read this article to know more. https://biotechhealthx.com/biotech-news/why-alpha-cognition-acog-could-be-the-next-big-alzheimers-breakthrough-stock/
0 · Reply